NCT01406756 arm group 0846b46187d2af04ee0e885bc01b9e1c [clinicaltrials_resource:NCT01406756/arm-group/0846b46187d2af04ee0e885bc01b9e1c]
clofarabine [clinicaltrials_resource:0bf7cae7bb2b1102dcb78c039b5bf957]pegaspargase [clinicaltrials_resource:4281720106c16a494fd491a3a798eabd]vincristine sulfate [clinicaltrials_resource:a84deb85619fcd56d9ce70e77547e24e]etoposide [clinicaltrials_resource:adb41d3cd17ab5447f9bb8eaa7369732]cyclophosphamide [clinicaltrials_resource:b4a6fc078e9195e02671a1672bd3e789]Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia [clinicaltrials:NCT01406756]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01406756 arm group 0846b46187d2af04ee0e885bc01b9e1c [clinicaltrials_resource:NCT01406756/arm-group/0846b46187d2af04ee0e885bc01b9e1c]
Bio2RDF identifier
NCT01406756/arm-group/0846b46187d2af04ee0e885bc01b9e1c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 46b46187d2af04ee0e885bc01b9e1c
description [clinicaltrials_vocabulary:description]
Patients receive clofarabine I ...... therapy as in arm B VHR-ALL C.
identifier
clinicaltrials_resource:NCT01406756/arm-group/0846b46187d2af04ee0e885bc01b9e1c
title
NCT01406756 arm group 0846b46187d2af04ee0e885bc01b9e1c
@en
type
label
NCT01406756 arm group 0846b461 ...... 6b46187d2af04ee0e885bc01b9e1c]
@en